The National Institute for Health and Care Excellence (NICE) has in draft guidance recommended Xiapex (clostridial collagenase for injection) for...
Endo International plc announced that the FDA has accepted for review the original Biologics License Application (BLA) for collagenase clostridium...
Peyronie's disease was described by Francois de la Peyronie in 1743, a battlefield surgeon and Commander of the Medical Corps.
Endo International plc announced that Phase III data evaluating Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery , the official journal of the American Society for Dermatologic Surgery.
Endo International plc announced that clinical data from a Phase III investigational study of collagenase clostridium histolyticum (CCH) for the...
Swedish Orphan Biovitrium (Sobi) announced that the EU Commission has approved Xiapex (collagenase clostridium histolyticum) for the treatment of adult...
Endo International announced that new post-hoc data from two Phase III studies of Xiaflex (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting. A post-hoc analysis of pooled data from two randomized, double-blind, placebo-controlled studies Phase III trials was conducted to evaluate incremental changes in penile curvature over the course of CCH treatment in men with PD. The analysis included men who received at least one injection of study medication.
Actelion will acquire from Auxilium Pharma exclusive rights to commercialise Xiaflex (collagenase Clostridium histolyticum) as a treatment for two rare...